29118259Ishihara J, Fukunaga K, Ishihara A, Larsson HM, Potin L, Hosseinchi P, Galliverti G, Swartz MA, Hubbell JAScience translational medicineAntineoplastic Agents; Extracellular Matrix; Immunotherapy; Melanoma, ExperimentalAnimals; Antibodies; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Disease Models, Animal; Extracellular Matrix Proteins; Fibrinolysin; Genetic Engineering; Heparin; Immunity; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Peptides; Placenta Growth Factor; Treatment OutcomeMatrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 08; 9(415).Sci Transl Med2017-11-08T00:00:002017Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD000818Living Beings1457265180.249646AnimalsJeffreyHubbell3Wp8CaMQFeD5hHlsaUXv9Gq0+s+oJeffrey Hubbell41.7886000000000087.598699999999993473Hubbell, JeffreyBarry L. MacLean ProfessorMelodySwartzMelody Swartz41.7886000000000087.598699999999993497Swartz, MelodyProfessorD008546Disorders421030.932219Melanoma, ExperimentalAuthorship 1128487Authorship 11284960.1605680.1605682authors10.2520has subject areaD005818Procedures711140.938256Genetic EngineeringD007167Procedures1836270.66599ImmunotherapyD005109Anatomy912310.871252Extracellular MatrixD008810Living Beings55730870.605697Mice, Inbred C57BLPritzker Institute for Molecular EngineeringD006493Chemicals & Drugs1031750.921807HeparinD016326Chemicals & Drugs631230.937767Extracellular Matrix ProteinsD015496Anatomy1524250.791566CD4-Positive T-LymphocytesD016246Anatomy641230.898031Lymphocytes, Tumor-InfiltratingD016896Concepts & Ideas101179490.402421Treatment OutcomeD018414Anatomy1605560.744866CD8-Positive T-LymphocytesD060908Chemicals & Drugs491350.947137CTLA-4 AntigenD000906Chemicals & Drugs2013490.840183AntibodiesD00007248319700.940979Placenta Growth FactorD004195Disorders59222270.60194Disease Models, AnimalD005341Chemicals & Drugs11260.98847FibrinolysinD007109Physiology901340.907728ImmunityD010455Chemicals & Drugs2456390.756144PeptidesUniversity of Chicagotrue1Barry L. MacLean ProfessorBarry L. MacLean Professortrue1ProfessorProfessor